Anti-CD19 antibodies

Patent Pending Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production.[7][8] Since CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.[9] Since 2011 treatments targeting CD19 have begun to enter trials.[10][11][12] Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers.